Related Experiment Video
Updated: Feb 4, 2026
A Murine Model of Stent Implantation in the Carotid Artery for the Study of Restenosis
Published on: May 14, 2013
Endoscopic Transpapillary Gallbladder Stenting for Complicated Cholecystitis in Patients With Cirrhosis and High
Arka De1, Arpit Shastri1, Sweta Rose1
1Department of Hepatology, Post Graduate Institute of Medical Education and Research, Chandigarh, 160012, India.
Insights
Endoscopic transpapillary gallbladder stenting (ETGS) offers a safe and effective treatment for complicated cholecystitis in high-risk cirrhotic patients. This minimally invasive procedure provides high technical and clinical success rates, serving as a valuable therapeutic option.
Area of Science:
- Gastroenterology
- Hepatology
- Interventional Endoscopy
Background:
- Patients with cirrhosis and cholecystitis face high surgical risks.
- Endoscopic retrograde cholangiopancreatography (ERCP) is often indicated for these patients.
- Endoscopic transpapillary gallbladder stenting (ETGS) can bridge patients to cholecystectomy or offer long-term gallbladder drainage.
Purpose of the Study:
- To evaluate the technical feasibility, clinical outcomes, and safety of ETGS.
- To assess ETGS for complicated cholecystitis in cirrhotic patients with high surgical risk.
Main Methods:
- Retrospective review of adult cirrhotic patients who underwent ETGS for complicated cholecystitis (January 2021-March 2025).
- Primary indication for ERCP was choledocholithiasis with or without cholangitis.
- Outcomes included technical success, clinical success, procedure time, safety, symptom recurrence, and biliary event-free survival.
Main Results:
- Technical success was achieved in 85% of 40 patients; clinical success in 97% of those with technical success.
- 6-month and 12-month biliary event-free survival rates were 94% and 86.7%, respectively.
- Mild adverse events occurred in 5% of patients, with no significant difference in outcomes between one or two stents.
Conclusions:
- ETGS is a technically feasible and safe therapeutic option for complicated cholecystitis in cirrhotic patients.
- The procedure demonstrates high clinical success and favorable intermediate-term outcomes.
- ETGS is a valuable treatment for high-risk surgical candidates with gallbladder issues.
Background:
Patients with cholecystitis and underlying cirrhosis represent a high-risk group for surgical intervention. In patients otherwise meriting an endoscopic retrograde cholangiopancreatography (ERCP), endoscopic transpapillary gallbladder stenting (ETGS) can serve as a bridge to cholecystectomy while awaiting liver transplant or provide long-term gallbladder (GB) drainage in those who are not surgical candidates. We evaluated the technical feasibility, clinical outcomes and safety of ETGS for complicated cholecystitis in patients with cirrhosis and high surgical risk.
Methods:
Data of all adult cirrhotic patients with complicated cholecystitis who underwent ETGS between January 2021 and March 2025 were reviewed. Primary indication for ERCP was choledocholithiasis with or without cholangitis. Primary outcome was technical success of ETGS (successful deployment of at least one GB stent). Secondary outcomes included procedure time, safety, clinical success (symptom resolution with improvement in laboratory parameters within 72-h of stent insertion), symptom recurrence, 6-month and 12-month biliary event-free survival, and differences in outcomes among patients with one or two GB stents.
Results:
Among 40 patients (age: 56.9 ± 14.3 years, 62.5% females, model for end-stage liver disease score: 16.4) with cirrhosis taken up for ETGS, technical success was achieved in 34 (85%) patients. Among those with technical success, clinical success was achieved in 33 (97%) patients. One and two 7-Fr double-pigtail plastic stents were deployed in 13 (38.2%) and 21 (61.8%) patients, respectively. Elective stent exchanges were not done. The median follow-up duration was 13.5 (11-18) months. One (2.9%) patient had recurrent cholecystitis at 5 months. The 6- and 12-month biliary event-free survival rates were 94% and 86.7%, respectively. No significant difference in clinical success, symptom recurrence, or 6- and 12-month survival was observed among patients with one or two stents. Mild (grade I as per the Adverse events GastRointEstinal Endoscopy classification) procedure-related adverse events occurred in two (5%) patients.
Conclusion:
ETGS is a technically feasible and safe, therapeutic option for complicated cholecystitis in cirrhotic patients with high clinical success and favourable intermediate-term outcomes.
More Related Videos
Related Concept Videos
01:17Gallbladder
The gallbladder's anatomy consists of three regions: the fundus, body, and neck. Extending from the neck, the cystic duct joins...
01:11Observational Studies
There are three types of observational studies – Prospective, retrospective, and cross-sectional.
Prospective Study
Prospective studies, also known as longitudinal or cohort studies, are carried out by collecting future data from groups sharing similar characteristics. One...
01:26Endoscopic Studies II: Thoracocentesis
Description
Excess pleural fluid or air may accumulate in some respiratory disorders in the thoracic cavity. To treat pleural effusion, a physician conducts thoracentesis by carefully piercing the chest wall and entering...
01:30Endoscopic Studies I: Bronchoscopy and Thoracoscopy
Bronchoscopy
Description
Bronchoscopy is a procedure that involves direct visualization of the larynx, trachea, and bronchi for diagnostic and therapeutic purposes. A flexible fiber optic or rigid bronchoscope is used to carry out the procedure. The fiber-optic bronchoscope is more frequently used due...
01:26Diseases of the Liver and Gallbladder
Cirrhosis is characterized by the scarring of hepatic lobules in the liver, which are replaced by fibrous tissue, affecting the liver's normal functioning. NAFLD, on the other hand, is caused by an excessive build-up of fat in the liver, not...
02:30Naturalistic Observations